Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration

Terada, Naoki; Maughan, Benjamin L.; Akamatsu, Shusuke; Kobayashi, Takashi; Yamasaki, Toshinari; Inoue, Takahiro; Kamba, Tomomi; Ogawa, Osamu; Antonarakis, Emmanuel S.

doi:10.1111/iju.13346

Cited by 52 publications

(39 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have been a number of studies reporting sequential use of ASIs, namely enzalutamide followed by abiraterone [28][29][30][31][32] and abiraterone followed by enzalutamide (Table 3). [31][32][33][34][35][36][37][38] Data seem to show a blunted effect of each after the use of the other, suggesting cross-resistance.…”

Section: Sequential Therapy Using Asismentioning

confidence: 99%

See 1 more Smart Citation

Current treatment strategies for advanced prostate cancer

et al. 2017

View full text Add to dashboard Cite

During the past decade, treatment strategies for patients with advanced prostate cancer involving stage IV (T4N0M0, N1M0 or M1) hormone-sensitive prostate cancer and recurrent prostate cancer after treatment with curative intent, as well as castration-resistant prostate cancer, have extensively evolved with the introduction and approval of several new agents including sipuleucel-T, radium-223, abiraterone, enzalutamide and cabazitaxel, all of which have shown significant improvement on overall survival. The appropriate use of these agents and the proper sequencing of these agents are still not optimized. The results of several recently reported randomized controlled trials and retrospective studies could assist in developing a treatment strategy for advanced prostate cancer. In addition, prospective studies and molecular characterization of tumors to address these issues are ongoing.

show abstract

Section: Sequential Therapy Using Asismentioning

confidence: 99%

“…[31][32][33][34][35][36][37][38] Data seem to show a blunted effect of each after the use of the other, suggesting cross-resistance. It remains unclear which patients benefit from one agent as the first agent compared with the other.…”

Section: Sequential Therapy Using Asismentioning

confidence: 99%

Current treatment strategies for advanced prostate cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Terada et al . showed that ABI‐to‐ENZA is superior to ENZA‐to‐ABI, which answered the question to some extent, but this study has several important limitations that should be understood with caution . First, this study was retrospective, and baseline characteristics between the USA and Japan were largely different.…”

mentioning

confidence: 83%

Editorial Comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration

Mitsuzuka

2017

Int J of Urology

View full text Add to dashboard Cite

“…Information on the included studies is presented in Table 1. All five studies were retrospective case-control studies [16][17][18][19][20].…”

Section: Systematic Review Processmentioning

confidence: 99%

Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Chung

Kang

Kim

et al. 2019

Cancers

View full text Add to dashboard Cite

Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity have been suggested. Therefore, we conducted a meta-analysis to compare oncologic outcomes between the treatment sequences of ABI-ENZA and ENZA-ABI in patients with mCRPC. The primary endpoint was a combined progression-free survival (PFS), and the secondary endpoint was overall survival (OS). A total of five trials on 553 patients were included in this study. Each of the included studies was retrospective. In two studies including both chemo-naïve and post-chemotherapy mCRPC patients, for ABI-ENZA compared with ENZA-ABI, pooled hazard ratios (HRs) for PFS and OS were 0.37 (p < 0.0001; 95% confidence intervals (CIs), 0.23-0.60) and 0.64 (p = 0.10; 95% CIs, 0.37-1.10), respectively. In three studies with chemo-naïve mCRPC patients only, for ABI-ENZA compared with ENZA-ABI, pooled HRs for PFS and OS were 0.57 (p = 0.02; 95% CIs, 0.35-0.92) and 0.86 (p = 0.39; 95% CIs, 0.61-1.21), respectively. The current meta-analysis revealed that ABI-ENZA had a significantly more favorable oncological outcome, but the level of evidence was low. Therefore, large-scale randomized trials may be needed.

show abstract

Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration

Cited by 52 publications

References 22 publications

Current treatment strategies for advanced prostate cancer

Current treatment strategies for advanced prostate cancer

Editorial Comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration

Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About